Can Fite Biopharma Ltd ADR Cash Flow-to-Debt Ratio
Can Fite Biopharma Ltd ADR cash flow-to-debt ratio. Can Fite Biopharma Ltd ADR (CANF) has a Cash Flow-to-Debt Ratio of -0.67x as of June 2025, meaning its operating cash flow of $-2.38 Million could theoretically repay -1% of its total liabilities ($3.54 Million) in one year. Check CANF operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Can Fite Biopharma Ltd ADR (2011–2025)
Cash flow-to-debt ratio of Can Fite Biopharma Ltd ADR from 2011 to 2025. Historical debt coverage capacity for Can Fite Biopharma Ltd ADR across 15 annual periods. Check Can Fite Biopharma Ltd ADR total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Can Fite Biopharma Ltd ADR Cash Flow-to-Debt Ratio by Year (2011–2025)
Can Fite Biopharma Ltd ADR cash flow-to-debt ratio by year from 2011 to 2025. Year-by-year debt coverage analysis for Can Fite Biopharma Ltd ADR. For the full cash flow conversion analysis, see Can Fite Biopharma Ltd ADR cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.30x | $-9.02 Million | $3.92 Million | ▼ -10.9% |
| 2024 | -2.07x | $-7.64 Million | $3.68 Million | ▲ +8.0% |
| 2023 | -2.25x | $-8.44 Million | $3.75 Million | ▼ -0.4% |
| 2022 | -2.25x | $-10.80 Million | $4.81 Million | ▼ -33.7% |
| 2021 | -1.68x | $-9.86 Million | $5.87 Million | ▲ +52.0% |
| 2020 | -3.50x | $-12.06 Million | $3.45 Million | ▼ -85.0% |
| 2019 | -1.89x | $-10.83 Million | $5.73 Million | ▼ -124.6% |
| 2018 | -0.84x | $-4.16 Million | $4.94 Million | ▲ +57.8% |
| 2017 | -1.99x | $-9.52 Million | $4.78 Million | ▼ -40.5% |
| 2016 | -1.42x | $-8.93 Million | $6.29 Million | ▼ -118.2% |
| 2015 | -0.65x | $-4.65 Million | $7.16 Million | ▲ +70.5% |
| 2014 | -2.20x | $-7.33 Million | $3.33 Million | ▲ +44.5% |
| 2013 | -3.97x | $-8.63 Million | $2.18 Million | ▼ -113.7% |
| 2012 | -1.86x | $-4.35 Million | $2.34 Million | ▲ +45.6% |
| 2011 | -3.41x | $-5.50 Million | $1.61 Million | — |